Investigation of the Mechanism of Jianxin Granules in Treating Diabetic Cardiomyopathy Based on Network Pharmacology and Clinical Trials
Objective:To investigate the mechanism of Jianxin Granules in treating diabetic cardiomyopathy(DCM)using network pharmacology and clinical trials.Methods:Network pharmacology tools and methods were used to obtain the active components and targets of Jianxin Granules and the disease targets of DCM.Key targets of Jianxin Granules acting on DCM were identified,and relevant signaling pathways were analyzed to explore possible molecular mechanisms.Clinical trials were conducted to further validate some targets.A total of 74 patients with diabetic cardiomyopathy who met the inclusion criteria were randomly divided into a treatment group and a control group,with 37 cases in each group.The control group received conventional Western medicine treatment,while the treatment group received Jianxin Granules in addition to the treatment received by the control group.Changes in echocardiography,Traditional Chinese Medicine(TCM)symptom scores,and the effect on inflammation targets were observed in both groups.Results:A total of 92 active components and 186 drug targets of Jianxin Granules were identified;780 genes related to DCM were found;91 direct interaction targets between the drug and disease were identified;and 19 core targets were screened through the construction of a protein-protein interaction(PPI)network.The top two targets were interleukin-6(IL-6)and interleukin-1β(IL-1β),with major pathways involving the IL-17 signaling pathway,TNF signaling pathway,lipid and atherosclerosis,and the AGE-RAGE signaling pathway in diabetic complications.Clinical trial results showed that Jianxin Granules improved the clinical symptoms of DCM patients.The improvement in TCM symptom scores and the overall effectiveness rate in the treatment group were better than those in the control group(P＜0.05).There was no significant difference in the levels of IL-6,IL-1β,NF-κB,and NT-proBNP between the two groups before treatment(P＞0.05).After treatment,the levels of IL-6,IL-1β,NF-κB,and NT-proBNP in both groups were significantly lower than before treatment(P＜0.05),and the levels in the treatment group were lower than those in the control group(P＜0.05).The overall effectiveness rate was 89.2%(33/37)in the treatment group,which was higher than 67.6%(25/37)in the control group(P＜0.05).Conclusion:Jianxin Granules can improve diabetic cardiomyopathy through multi-component,multi-target,and multi-pathway mechanisms.In particular,they play a significant role in regulating inflammatory responses by inhibiting IL-6 and IL-1β expression through the IL-17 signaling pathway.
万方数据
维普
